Should You Buy Pfizer (PFE) Before a Breakout Begins?

Group 1 - Pfizer Inc (NYSE:PFE) is trending as analysts expect a rally in major healthcare stocks, with a bullish outlook from Evan Seigerman of BMO Capital Markets [1][2] - The recent acquisition of Metsera, Inc. is seen as a strategic move for Pfizer to enhance its position in the obesity treatment market, with positive data supporting the acquisition [2] - Despite a 1% decline in Pfizer's stock this year, analysts believe that the company can achieve margin expansion and develop its pipeline effectively [2] Group 2 - Parnassus Investments has exited its position in Pfizer due to concerns over a weaker R&D pipeline and potential regulatory challenges, indicating reduced confidence in the company's turnaround [3] - The firm suggests that while Pfizer has investment potential, AI stocks may offer better returns with lower risk, reflecting a shift in investment focus [3]